The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
Applications include detailed scientific rationale and supporting clinical evidence
Expands bioprocessing footprint across Asia
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Subscribe To Our Newsletter & Stay Updated
